Earnings included compensation expenses related to equity awards. Excluding these special items, adjusted loss per share was 43 cents against a gain of 12 cents per share in the year-ago quarter.

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

A pioneering team at St Jude Children's Research Hospital in the US say they successfully treated a child diagnosed with SMA ...

Citi analyst David Lebowitz lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $64 from $67 and keeps a Buy rating on the ...

CompanyOverview\|NASDAQ:BIIB] Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares ...

Ionis Pharmaceuticals beats Q4 earnings, eyes sHTG market with TRYNGOLZA. Strong pipeline and cash position make it a ...

During Q4, Ionis reported revenues of $227 million, 68.1% above the $135 million estimated by analysts. That positive surprise was attributed in part to the successful launch and commercialization of ...

For the quarter ended December 2024, Ionis Pharmaceuticals (IONS) reported revenue of $227 million, down 30.2% over the same period last year. EPS came in at -$0.66, compared to -$0.06 in the year-ago ...

Ionis Pharmaceuticals (NASDAQ:IONS) stock gains as company reports strong Q4 results fueled by new product rollouts like ...

The U.S. senator says bipartisan work and region’s talent has helped LI become a ‘mecca of health innovation and research’ ...

In this episode, we reflect upon recent events, including our delicious Thanksgiving, Shane’s latest Spinraza injection, ...

A girl on Long Island is speaking out after a clinical trial for Spinal Muscular Atrophy was cut by President Trump ...